Teresa McCarthy, Chief Human Resources Officer, joined Avidity Biosciences in August 2020. Ms. McCarthy is responsible for developing and executing human resource strategies in support of Avidity's overall business plan and strategic direction. She brings to Avidity decades of experience as an organizational development and human resources consultant in the life science industry. Ms. McCarthy has worked with biotech and healthcare companies at all stages of development via her consulting firm, McCarthy Consultants Inc., and her long-term partnership with The Leadership Edge, Inc. Prior to consulting, Ms. McCarthy held leadership positions at Edwards Lifesciences, Baxter Cardiovascular Group, and IVAC Corporation and received an M.A. degree in Organizational Communication with an emphasis in International Business from San Diego State University.

Eric Mosbrooker joined Avidity Biosciences in August 2021 and serves as Chief Commercial Officer. He previously held the roles of Chief Strategy Officer and member of the Board of Directors at Avidity. Mr. Mosbrooker has more than 20 years of experience in global operations, with demonstrated leadership and experience in commercial operations, market access, product launches, and program leadership. He has expertise in multiple rare diseases, encompassing neuromuscular, metabolic, oncology and additional orphan conditions. He has worked in all treatment modalities including one-time gene therapy.  Prior to joining Avidity, Mr. Mosbrooker served as Chief Operations Officer for Cognoa, leading the commercial, program management, product, and business operations functions. Before Cognoa, he was Chief Commercial Officer at Audentes Therapeutics, overseeing the gene therapy business unit, and Senior Vice President of the Global Orphan Business Unit at Horizon Pharmaceuticals. He holds a B.S. in Industrial Engineering from the University of Wisconsin – Madison. 

John B. Moriarty, Jr., J.D. has served as our Chief Legal Officer and Corporate Secretary since August 2024. Prior to joining the Company, Mr. Moriarty served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Mirati Therapeutics, Inc. from May 2023 to January 2024, when it was acquired by Bristol-Myers Squibb Co. Previously, from September 2020 to April 2023, Mr. Moriarty served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Olema Pharmaceuticals, Inc., and from March 2018 to July 2020, he served as Executive Vice President, General Counsel and Secretary of Portola Pharmaceuticals, Inc., which was acquired by Alexion Pharmaceuticals, Inc. in July 2020. From September 2014 to February 2018, Mr. Moriarty served as Executive Vice President and General Counsel of Alexion Pharmaceuticals, Inc., and from December 2012 to September 2014, he served as Senior Vice President and General Counsel of Alexion. Prior to joining Alexion, he served as General Counsel and Senior Vice President at Elan Corporation plc, an Irish public limited company traded on the New York and Irish Stock Exchanges, and also served as a member of Elan’s Executive Management team from March 2010 to December 2012. Prior to assuming the role of General Counsel and Senior Vice President, Mr. Moriarty served as Senior Vice President, Law, Litigation and Commercial Operations at Elan from December 2008 to March 2010. From 2002 to 2008, Mr. Moriarty held various positions with Amgen Inc., including Executive Director and Associate General Counsel, Global Commercial Operations and Senior Counsel, Complex Litigation, Products Liability and Government Investigations. From 1999 through 2002 Mr. Moriarty was in private practice with a national law firm.  From 1994 to 1999, Mr. Moriarty served in various capacities in private practice focused on healthcare and as a healthcare fraud prosecutor in the U.S. Attorney’s Office and the Virginia Attorney General’s Office. Mr. Moriarty received a B.A. from the University of Virginia and a J.D. cum laude from the University of Georgia School of Law.

Kathleen Gallagher joined Avidity Biosciences in April 2021 and serves as Chief Program Officer. She previously held the roles of Senior Vice President and Global Program Head, Myotonic Dystrophy Type 1 (DM1) and Senior Vice President of Corporate Communications and Investor Relations. Ms. Gallagher brings more than 20 years of experience in the biopharmaceutical industry leading communications and investor relations in preclinical to commercial stage companies. Prior to joining Avidity, she was Vice President, Investor Relations and Corporate Communications at Akcea Therapeutics (acquired by Ionis Pharmaceuticals), where her communications strategy and relationship building expertise were essential through the development and commercial launches of rare disease therapies Tegsedi® and Waylivra®. Previously, she held roles of increasing responsibility during her 13-year tenure at Merrimack Pharmaceuticals, where she provided leadership and direction through multiple financing rounds including an IPO and through the launch of the pancreatic cancer therapy ONIVYDE®. Ms. Gallagher earned her B.S. degree in English from Boston University.

Charles Calderaro III, Chief Technical Officer, joined Avidity Biosciences in January 2025. He has more than 35 years of experience in biotechnology, pharmaceutical, and cell and gene therapy company operations and in CMC drug development. Prior to joining Avidity, Mr. Calderaro served as Chief Technical Officer for Shoreline Biosciences, where he was responsible for advancing programs in oncology and autoimmune diseases and developing scalable bioprocesses for manufacturing gene editing and cell therapies. Prior to Shoreline, he served as Global Head of Technical Operations at Kite Pharma, a Gilead Company, and Senior Vice President, Global Manufacturing at BioMarin. In addition, he previously held roles of increasing responsibility during his 14-year tenure at Genentech, a member of the Roche Group, and at Aventis Behring LLC (now CSL Behring). Mr. Calderaro was also previously a commissioned officer in the U.S. Navy. He earned his M.B.A. from Texas Christian University, his M.S. in Nuclear Engineering from the U.S. Naval Nuclear Power School, and his B.S. in Electrical Engineering from the University of Notre Dame. 

Kat Lange joined Avidity Biosciences in December 2024 and serves as Senior Vice President and Chief Business Officer. Ms. Lange has spent over 15 years in the life sciences and biotechnology industry, with demonstrated leadership and experience in fundraising, strategic advisory, business development and investor relations to help advance novel therapies for the treatment of neuromuscular diseases. Prior to joining Avidity, Ms. Lange served as Chief Financial Officer at Locanabio, leading the finance, investor relations and operations functions. Before Locanabio, she was an executive director in the healthcare investment banking group at J.P. Morgan where she executed more than $18 billion in equity and equity-linked financings and more than $27 billion in various business transactions. She earned a master's degree in management science from the Judge Business School at Cambridge University and a master's and bachelor's degree in natural sciences also from Cambridge University.